Numerous studies have reported deletions of IKZF1 to be an independent marker of adverse risk in ALL adjusting for age and cytogenetic ALL subtype, resulting in higher risk of relapse and substantially shortened survival [22, 30–35]. Here, IKZF1 is linked to acute lymphoblastic leukemia.